Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18848278 | 1.00 | PRKCA (0.35) | PRKCAMEN1GAAKMT2ATDP1 | |
| SCHEMBL18848225 | 1.00 | PRKCA (0.35) | PRKCAMEN1GAAKMT2ATDP1 | |
| SCHEMBL18848340 | 0.92 | MAOA (0.33) | PRKCAMEN1GAAKMT2ATDP1 | |
| SCHEMBL18848240 | 0.92 | MAOA (0.33) | PRKCAMEN1GAAKMT2ATDP1 | |
| SCHEMBL18848283 | 0.92 | MAOA (0.33) | PRKCAMEN1GAAKMT2ATDP1 | |
| SCHEMBL1887538 | 0.85 | PRKCA (0.34) | PRKCAMEN1GAAKMT2ATDP1 | |
| SCHEMBL11923117 | 0.82 | CHRNB2 (0.38) | PRKCATDP1 | |
| SCHEMBL18848279 | 0.80 | TSHR (0.38) | — | |
| SCHEMBL18848362 | 0.80 | TSHR (0.38) | — | |
| SCHEMBL18848224 | 0.80 | TSHR (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738620-B2 | Trientine prodrugs, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170129868-A1 | TRIENTINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129868-A1 | TRIENTINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | SLC10A1, ABCB11, SLC10A2 | PRKCA 4165/4885MEN1 825/4885GAA 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.